English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Pioglitazone use and risk of bladder cancer in diabetic patient is one of the major causes of morbidity and mortality. Increasing evidence from the clinical studies suggested increased risk of bladder cancer with higher dose and longer duration of pioglitazone use. In contrast, few studies reported non-significant association with pioglitazone use and risk of bladder cancer in T2DM patients. Therefore, we aimed to review and summarize the available clinical data describing the risk of bladder cancer associated with pioglitazone treatment.

Do We Still Need Pioglitazone for The Management of Type 2 Diabetes Mellitus? A Peep In To Risk of Bladder Cancer in Diabetic Population